Physician profile
Melissa Johnson
NPI 1104230598
$1,919.71
in general payments reported to CMS, 2019-2025
28 companies · $181 in 2025
The $181 reported for 2025 was more than what a typical Clinical Nurse Specialist provider received nationally (typical 2025 total: $150).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $396 · 2022: $522 · 2023: $553 · 2024: $268 · 2025: $181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,002.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,001.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $431.02 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $164.57 | 2021-2024 | |
| Novo Nordisk INC | $159.37 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Janssen Pharmaceuticals, INC | $147.65 | 2021-2022 | |
| Amgen INC. | $129.56 | 2021-2024 | Prolia, Evenity |
| Lilly USA, LLC | $108.92 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.72 | 2021-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $96.95 | 2021-2023 | |
| Conmed Corporation | $77.10 | 2024 | Airseal |
| Astellas Pharma US INC | $53.66 | 2021-2023 | Veozah |
| Pfizer INC. | $49.34 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $43.64 | 2021 | |
| Glaxosmithkline, LLC. | $42.19 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Axsome Therapeutics, INC. | $40.37 | 2023 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $32.17 | 2021-2025 | Hyqvia |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $28.52 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $25.54 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $23.60 | 2021-2022 | |
| Merz Pharmaceuticals, LLC | $23.28 | 2024 | Inbrija, Xeomin |
| Sumitomo Pharma America, INC. | $22.84 | 2023 | Gemtesa |
| Xeris Pharmaceuticals, INC. | $22.15 | 2023 | Gvoke Hypopen |
| Biodelivery Sciences International, INC. | $18.68 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $16.53 | 2023 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.34 | 2021 | |
| Idorsia Pharmaceuticals US INC | $13.29 | 2023 | Quviviq |
| Philips North America LLC | $12.86 | 2023 | |
| Almatica Pharma LLC | $11.75 | 2022 | |
| Sanofi-Aventis U.S. LLC | $11.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.